Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07677163 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Trial of MK-1403 in Healthy Participants (MK-1403-007)

StatusCompleted
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial completed Primary and study completion dates changed from estimate of Sep 22, 2026 to Oct 5, 2026 Show 1 more changeShow less
    • Primary and study completion dates changed from estimate of Sep 22, 2026 to Oct 5, 2026
  2. Lead sponsor: Merck Sharp & Dohme LLC to Merck Sharp & Dohme LLC Enrollment closed, study ongoing · Study site revised · Eligibility criteria expanded, about 4 words Show 3 more changesShow less
    • Enrollment closed, study ongoing
    • Study site revised
    • Eligibility criteria expanded, about 4 words
  3. Recruitment opened Study sites: 0 to 1 · Start date changed from estimate of Jul 29, 2026 to Aug 14, 2026v2 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Jul 29, 2026 to Aug 14, 2026
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Merck (MSD)
407 trials monitored
See 29 trials at risk
The purpose of this trial is to learn about a trial medicine called MK-1403. Researchers designed MK-1403 to treat a type of heart and blood vessel disease called atherosclerotic cardiovascular disease (ASCVD). Before giving a trial medicine to people with a health condition, researchers first do clinical trials in healthy people. This trial will help researchers learn about the safety of MK-1403 and if participants tolerate it. Tolerate means participants receive the trial medicine and they do not need to stop taking it due to health problems. The trial will also measure what happens to MK 1403 in a healthy person's body over time.
Trial Details
NCT Number NCT07677163
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Healthy
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov